ARS Pharmaceuticals, Inc. (SPRY) earnings date
Mar 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 15 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 13, 2026 | after close | 44 | 8-K |
| Q1 FY2026 | Fri, May 15, 2026 | before open | 45 | 8-K |
| Q4 FY2025 | Mon, Mar 9, 2026 | before open | 68 | 8-K |
| Q3 FY2025 | Mon, Nov 10, 2025 | before open | 41 | 8-K |
| Q2 FY2025 | Wed, Aug 13, 2025 | before open | 44 | 8-K |
| Q1 FY2025 | Wed, May 14, 2025 | before open | 44 | 8-K |
| Q4 FY2024 | Thu, Mar 20, 2025 | before open | 79 | 8-K |
What they guided beta
| Q3 FY2026 | "Total Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy ® neffy U.S. market share reached 5% overall and 9% in field-targeted accounts, supporting the company’s updated targeted provider commercial strategy Reduced SG&A spend reflected in Q3 operating expenses; reaffirm path to cash flow breakeven by year-end 2027" exhibit |
| Q3 FY2026 | "“Market share grew where our field team engaged; operating expenses were in line with guidance, including a 42% reduction in third-quarter SG&A expenses from the first-half 2026 quarterly average; and ARS-2 is on track for interim Phase 2b data in the first quarter of 2027." exhibit |
| Q3 FY2026 | "Interim data from the Phase 2b trial are expected in the first quarter of 2027, with full data later in 2027, which will inform the design of a potential Phase 3 registration program." exhibit |
| Q3 FY2026 | "Spending is tracking in line with second-half 2026 guidance of $114 million to $126 million in aggregate SG&A and R&D expenses, including stock-based compensation. o SG&A Expenses: Third-quarter 2026 SG&A expenses were $43.5 million, compared with $74.8 million for the third quarter of 2025, primarily reflecting the discontinuation of linear TV and broad consumer advertising, along with more focused commercial investment. o R&D Expenses: Third-quarter 2026 R&D expenses were $18.3 million, primarily related to a one-time $12.5 million payment related to a license agreement for exclusive worldwi" exhibit |
| Q3 FY2026 | "Based on its current expense base plan, the company continues to expect to reach cash flow breakeven by the end of 2027." exhibit |
| Q2 FY2026 | "Commercial investment realigned toward targeted provider engagement, significantly reducing total operating expenses for 2H 2026 and supporting an expected path to cash flow breakeven by the end of 2027 Commercial operations strengthened with appointment of Meg Smith as Chief Commercial Officer and completed expansion of field sales organization Interim data from Phase 2b trial in chronic spontaneous urticaria (CSU) expected in Q1 2027; no FDA-approved on-demand treatment currently exists for acute CSU flares Conference call to be held today, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET " exhibit |
| Q2 FY2026 | "Enhanced Financial Discipline and Updated 2H 2026 Expense Guidance ARS Pharma announced the re-alignment of its operating expenses to support building a durable, profitable business." exhibit |
| Q2 FY2026 | "Operating expense : ARS Pharma expects its aggregate SG&A and R&D expenses for the second half of 2026 to be in the range of $114 million to $126 million, which includes stock-based compensation expense of approximately $14 million to $16 million." exhibit |
| Q2 FY2026 | "As a result, total cash-based SG&A and R&D expenses for the second half of 2026 are expected to be in the range of $100 million to $110 million, driven by a more than 40% reduction in SG&A cash-based expenses from the first half of 2026, with a favorable trend planned to continue through full-year 2027." exhibit |
| Q2 FY2026 | "Path to cash flow breakeven : Based on its revised cash-based expense plan, ARS Pharma anticipates a path to reaching cash flow breakeven by the end of 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SPRY
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SPRY
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/SPRY/"><img src="https://veritasdata.dev/embed/SPRY.svg" alt="SPRY earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/SPRY/)
Script
<script async src="https://veritasdata.dev/embed/SPRY.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SPRY"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.